Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 11/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | PDE6D | O43924 | 1/20 | 0.48 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.47 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1978779 | 1.00 | HMGCR (0.55) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL30799327 | 1.00 | HMGCR (0.55) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL2050597 | 1.00 | HMGCR (0.55) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL1978780 | 1.00 | HMGCR (0.55) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL8239672 | 1.00 | HMGCR (0.55) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL7933980 | 1.00 | HMGCR (0.55) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL9611179 | 0.94 | HMGCR (0.52) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL3259413 | 0.92 | HMGCR (0.56) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL13100382 | 0.92 | HMGCR (0.56) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL13637135 | 0.92 | HMGCR (0.46) | HMGCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110245285-A1 | PROCESS FOR PREPARATION OF ROSUVASTATIN ACETONIDE CALCIUM | BIOCON LIMITED (IN) | 2011-10-06 | — | — | US | claimed |
| CN-115710256-A | Intermediate compound for preparing rosuvastatin calcium and synthetic method thereof | 淄博矿业集团有限责任公司 | 2023-02-24 | — | — | CN | disclosed |
| CN-113956243-A | Rosuvastatin intermediate and preparation method thereof | 宣城美诺华药业有限公司 | 2022-01-21 | — | — | CN | disclosed |
| CN-113929667-A | Rosuvastatin intermediate, preparation method of intermediate and preparation method of rosuvastatin ester | 宣城美诺华药业有限公司 | 2022-01-14 | — | — | CN | disclosed |
| CN-107298675-B | Preparation method of rosuvastatin calcium intermediate | 浙江美诺华药物化学有限公司 | 2020-08-11 | — | — | CN | disclosed |
| US-20110245285-A1 | PROCESS FOR PREPARATION OF ROSUVASTATIN ACETONIDE CALCIUM | BIOCON LIMITED (IN) | 2011-10-06 | — | — | US | disclosed |
| EP-2334667-A1 | A PROCESS FOR PREPARATION OF ROSUVASTATIN ACETONIDE CALCIUM | Biocon Limited (IN) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010029561-A1 | A PROCESS FOR PREPARATION OF ROSUVASTATIN ACETONIDE CALCIUM | BIOCON LIMITED (IN) | 2010-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245285-A1 | PROCESS FOR PREPARATION OF ROSUVASTATIN ACETONIDE CALCIUM | HMGCR, DHCR7, CYP4A11 | HMGCR 1/4885ALDH1A1 1310/4885CYP3A4 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.